Obicetrapib is an oral, once-daily, low-dose, safe, and tolerable CETP inhibitor under development for the treatment of dyslipidemia, CVD risk, and Alzheimer’s disease. This evidence concerns the gene CETP and early-onset autosomal dominant Alzheimer disease.